Sight Sciences (SGHT) Investor presentation summary

Strategic vision and market focus

• Focuses on innovation in two large, underserved markets: glaucoma and dry eye disease.

• Emphasizes interventional approaches over traditional daily eye drops, aiming to elevate standards of care.

• Leverages a shared customer base and commercial synergies between glaucoma and dry eye treatment teams.

• Over 400,000 glaucoma and 75,000 dry eye procedures performed to date, indicating significant market penetration.

• Strategic roadmap prioritizes early procedural intervention to reduce patient burden and improve outcomes.

Interventional dry eye: TearCare system

• TearCare targets meibomian gland dysfunction (MGD), a root cause of dry eye, with a comprehensive, FDA-cleared, open-eye, thermal-activated therapy.

• SAHARA randomized controlled trial demonstrated TearCare's superiority over Restasis in improving tear breakup time and durability of effect for up to two years.

• U.S. dry eye market estimated at $2.4 billion, with ~19 million diagnosed patients; up to 86% linked to MGD.

• TearCare has performed over 75,000 procedures and is scaling commercially, targeting 6,500 physicians and leveraging synergies with glaucoma customers.

• Published analyses show TearCare offers economic savings for payors compared to prescription medications.

Interventional glaucoma: OMNI surgical system

• OMNI system provides comprehensive, implant-free minimally invasive glaucoma surgery (MIGS) for primary open-angle glaucoma (POAG).

• Over 400,000 OMNI procedures performed, supported by robust clinical evidence and broad FDA indication.

• OMNI treats all three resistance points in the conventional outflow pathway, with efficacy demonstrated in both standalone and combination cataract procedures.

• U.S. glaucoma market estimated at $6 billion, with over 4 million diagnosed patients.

• Addresses all six MIGS POAG categories, with a $5 billion standalone and $1 billion combination cataract opportunity.